Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis

BACKGROUND: Aflibercept has been approved for the treatment of metastatic colorectal cancer for more than a decade, but its antiangiogenesis adverse effect profile during treatment remains unclear. This study is conducted to systematically review the risk of antiangiogenic adverse events in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Pu, Han, Chunyan, Reyila, Abudurousuli, Liu, Diyue, Hong, Wenying, Liu, Jiaxin, Zhang, Jinzi, Han, Xiao, Li, Xialei, Huang, Mengjie, Fan, Siyuan, Kaierdebieke, Ayidana, Wu, Xiaoyu, Huang, Xiaolu, Guo, Weirui, Liu, Siyu, Bian, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476758/
https://www.ncbi.nlm.nih.gov/pubmed/37657052
http://dx.doi.org/10.1097/MD.0000000000034793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476758/
https://www.ncbi.nlm.nih.gov/pubmed/37657052
http://dx.doi.org/10.1097/MD.0000000000034793

Ejemplares similares